Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN ULTRA versus LUZU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN ULTRA versus LUZU.
LOTRIMIN ULTRA vs LUZU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butenafine hydrochloride is a synthetic antifungal agent that inhibits the enzyme squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to fungal cell death.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Adults: Apply butenafine hydrochloride 1% cream topically once daily for 7 days for tinea pedis; for tinea cruris and tinea corporis, apply once daily for 14 days.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours (range 20-50 hours), supporting once-daily topical application.
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Primarily fecal (approx. 80%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Category C
Category C
Topical Antifungal
Topical Antifungal